News

Lexington Cardiovascular Health Monitor Performing as Designed with First Clinical Patients

VANCOUVER, British Columbia, March 05, 2018 — Lexington Biosciences, Inc. (CSE:LNB) (LXGTF) (the “Company” or “Lexington”), a development-stage medical device company, is pleased to provide an early update of its clinical trial and patient enrollment. As previously announced, the Company’s HeartSentry device is undergoing clinical studies designed to measure the safety and effectiveness of the

Read More

The Lexington News Issue #2

Dear Lexington Biosciences Shareholders & Friends, I am pleased to provide a continuing overview of recent and future events underway here at Lexington Biosciences. The purpose of these updates is to keep you informed of the progress of the company in regards to our technology, operations, and  nancing. For those of you new to our

Read More

Lexington Begins HeartSentry Clinical Trial

Trial designed to study safety and effectiveness for a non-invasive diagnostic device for cardiovascular health management VANCOUVER, British Columbia, Feb. 20, 2018 — Lexington Biosciences, Inc. (CSE:LNB) (OTCQB:LXGTF) (the “Company” or “Lexington”), a development-stage medical device company, is pleased to announce commencement of its clinical trial and first patient enrollment.  These clinical studies are designed to measure

Read More

Lexington Delivers 1st Generation HeartSentry for Clinical Trials

Device completes software, mechanical and electrical tests in preparation for human study VANCOUVER, BRITISH COLUMBIA – February 13, 2018 – Lexington Biosciences, Inc. (CSE: LNB) (OTCQB: LXGTF) (the “Company” or “Lexington”), a development-stage medical device company, is pleased to advise that its HeartSentry 1st generation product has successfully passed all requisite bench tests in preparation for

Read More

Lexington Receives Approval to Commence Clinical Study

Lexington Biosciences is pleased to announce its recent application for Institutional Review Board (“IRB”) approval of its pilot clinical study at Diablo Clinical Research has been approved. 

Lexington Completes IRB Submission in Preparation for Clinical Study

Another milestone achieved as the Company moves towards HeartSentry human trials Lexington Biosciences, Inc. (CSE:LNB) (OTCQB:LXGTF) (the “Company” or “Lexington”), a development-stage medical device company, is pleased to announce it has completed its requisite documentation and submitted an application for Institutional Review Board (“IRB”) approval of its pilot clinical study. In preparation for commercialization of the

Read More

Lexington Biosciences Announces Exercise of Warrants

VANCOUVER, British Columbia, Jan. 11, 2018 — Lexington Biosciences, Inc. (CSE:LNB) (OTCQB:LXGTF) (the “Company” or “Lexington”), a development-stage medical device company, is pleased to announce that 5,497,500 share purchase warrants which were issued on November 24, 2016 and December 20, 2016 have been exercised on or before December 20, 2017 at a price of $0.30 per warrant

Read More

1 2 3

Archives

Categories

Newsletter Updates

If you haven’t already done so, signup here to receive future editions and the latest company news direct to your inbox.

Latest News